During inflammatory reactions, the production and release of chemotactic factors guide the recruitment of selective leukocyte subpopulations. HMGB1 and the chemokine CXCL12, both released in the microenvironment, form a heterocomplex, which exclusively acts on the chemokine receptor CXCR4, enhancing cell migration and, in some pathological conditions such as Rheumatoid Arthritis, exacerbating the immune response. An excessive cell influx at the inflammatory site can be diminished by disrupting the heterocomplex.
Introduction
Chemokines are key regulators of leukocyte migration and play fundamental roles both in physiological and pathological immune responses. 1 Chemokine receptors differentially expressed by all leukocytes and many non-hematopoietic cells, including cancer cells, constitute the largest branch of the γ subfamily of rhodopsin-like G protein-coupled receptors (GPCR). In modern pharmacology, this receptor superfamily represents the most successful target of small molecule inhibitors for the treatment of a variety of human diseases. 2 In the last 25/30 years, an impressive amount of preclinical and clinical evidence has progressively validated the role of chemokines and their receptors in immune-mediated diseases. 3, 4 Furthermore, in the last decade, several studies have pointed out how the activity of chemokines on cell migration can be modulated by their binding to other chemokines or proteins released in inflammation. 5, 6 In particular, our group has shown that High Mobility Group Box 1 (HMGB1), an alarmin released under stress conditions, forms a heterocomplex with the chemokine CXCL12, favoring cell migration via the activation of the chemokine receptor CXCR4 in the presence of low concentration of CXCL12, which normally is insufficient to trigger a cellular response. 7 Moreover, we have demonstrated that synergism between CXCL12 and HMGB1 sustains inflammation in Rheumatoid Arthritis (RA). 8 These observations suggest that the identifications of molecules able to suppress the interaction between chemokines and their modulators could lead to the discovery of effective inhibitors able to promote resolution of inflammation.
HMGB1 is a highly conserved nuclear protein expressed in bacteria, yeast, plants and in all vertebrate cells. Structurally, it is composed by two homologous, but not identical domains, BoxA and BoxB, and a negatively charged C-terminal tail (Figure 1 ). 9 In addition to its nuclear function, HMGB1 is released under inflammatory conditions or by necrotic cells, and acts as a damage-associated molecular pattern molecule (DAMP). 10, 11 In the extracellular space, HMGB1 can be present in different redox states, depending on the presence of an intramolecular disulfide bond between two cysteines at position 23 and 45. 12 Reduced HMGB1, once released in the extracellular space, can form a heterocomplex with CXCL12 and synergistically promote, via CXCR4, the recruitment of leukocytes to inflammatory sites. 7, 8, 13 Moreover reduced HMGB1 can bind to the receptor for advanced glycation endproducts (RAGE) to induce CXCL12 secretion and authophagy. 14 
Once
oxidized, by reactive oxidative species present in the extracellular space, HMGB1 binds to the Toll-like Receptor 4 (TLR4) leading to activation of the nuclear factor kappa-B (NF-kB) and transcription of cytokines, and chemokines. 12, 15 To date, despite the importance of this target, only few inhibitors of the CXCL12/HMGB1 interaction, or of the HMGB1 functions have been identified. 16, 17, 18, 19 Currently, glycyrrhizin is the most potent and the best structurally characterized inhibitor of the CXCL12/HMGB1 heterocomplex, but has a low affinity for HMGB1 (K d ~ 150 μM), and it lacks of specificity. 7, 16, 19 Peptides are receiving increasing attention due to their ability in targeting large surfaces as those involved in protein-protein interactions (PPI), and to promising pre-clinical and clinical results. 20, 22 Recent efforts have been put into the development of innovative strategies to overcome their intrinsic limitations such as low bioavailability and poor metabolic stability. 21, 22, 23 It is estimated that more than 400 peptides are in clinical development, and 60 are already available for therapeutic use in different countries. 24, 25 Here, we report the computationally driven identification of a novel high affinity nonapeptide able to inhibit the formation of the CXCL12/HMGB1 heterocomplex and to abolish the synergistic effect on cell migration in CXCR4 transfected cells and in human monocytes, without affecting the ability of HMGB1 to trigger TLR4. The peptide is the strongest HMGB1 binder reported so far, with an affinity K d of 0.8 µM.
Results

Design of a peptide inhibitor of the CXCL12/HMGB1 interaction
Taking advantage of the known interaction between glycyrrhizin and HMGB1, 16 we developed a computational pipeline to identify novel and selective peptide inhibitors of the CXCL12/HMGB1 interaction (Figure 2A ). We generated a model of the glycyrrhizin/BoxA complex consistent with the results of previously reported NMR chemical shift perturbation studies ( Figure 2B ). 16 To maximize the heterogeneity of the peptides considered in our screening, we generated a library of 40.000 nonapeptides with a randomly selected sequence. All peptides were docked in the glycyrrhizin binding site and ranked according to the binding energy of the corresponding peptide/HMGB1 complex ( Figure 2C , See Materials and Methods). Finally, aiming to reduce the number of potential false positives, the best 100 ranking peptides were re-docked to BoxA, with the program Glide, 26 without constraining the algorithm to explore only the glycyrrhizin binding site.
The peptides resulting after these calculations were visually inspected and only the best GSCORE (a scoring function aimed to estimate binding affinity) pose of 57 peptides with a glycyrrhizin-like binding mode were retained for further analysis (Supplementary Table 1 ).
Several studies have shown that approximated free energy methods like MM-GBSA, 27, 28 especially when coupled with long MD simulations, can be a valuable help in selection of active molecules in virtual screening investigations. 29, 30 Therefore, a 500 ns long MD simulation was performed for each of the 57 peptides obtained from docking calculations.
Those detaching from the BoxA binding pocket during the simulations (14 out of 57) were considered unstable and not further analyzed in MM-GBSA calculations (Supplementary Table 1 ).
Based on the MM-GBSA score, 13 different peptides were selected to be tested in vitro (Table 1 , and Supplementary Figure 1 ).
In vitro assessment of the identified peptides.
The 13 identified peptides were tested in in vitro chemotaxis assay, to evaluate their efficacy as inhibitors of the CXCL12/HMGB1-induced migration, on a murine cell line expressing the human CXCR4. Our experiments showed that 4, out of 13 peptides tested, efficaciously inhibited the enhanced migration induced by the CXCL12/HMGB1 heterocomplex ( Figure 3A ). Of note, the inhibition observed using 100 µM of HBP05, HBP07, HBP08, or HBP12 was similar or better than the one observed using glycyrrhizin at 200 µM ( Figure 3A) . Further experiments performed with CXCL12 alone, showed that HBP07 and HBP08 do not affect CXCL12-induced cell migration, while HBP05 and HBP12 inhibit the migration induced by the chemokine alone ( Figure 3B ), and therefore were not used for further experiments. HBP07 and HBP08 were then tested on primary human monocytes.
Only the HBP08 significantly blocked the activity of the heterocomplex ( Figure 3C ), without altering the migration induced by CXCL12 alone ( Figure 3D ), and exhibited no toxicity on both cell types (data not shown).
Selective activity of the HBP08 peptide
In the extracellular space oxidized HMGB1, through the binding to TLR4, activates the NF-kB pathway and induces the transcription of several pro-inflammatory cytokines. 12, 15 In order to determine whether HBP08 was a selective inhibitor of the activity of the CXCL12/HMGB1 heterocomplex or could also prevent the binding of HMGB1 to its receptor TLR4, we performed a cytokine release assay on monocytes treated with HMGB1 alone, or in the presence of HBP08. Monocytes stimulation with HMGB1 induced a significant release of IL-6 and TNF, which could be blocked by treatment with a neutralizing antibody against TLR4 ( Figure 4A , B). HBP08 did not induce IL-6 or TNF release and did not block the HMGB1-mediated release of these cytokines. These data indicate that HBP08 selectively inhibits the CXCL12/HMGB1 heterocomplex activity, leaving HMGB1 able to trigger TLR4.
Characterization of the HMGB1-HBP08 interaction
Microscale thermophoresis (MST) was performed to determine the affinity of HBP08 to HMGB1, resulting in a K d of 0.8±0.1 μM ( Figure 5 ). The affinity of the identified peptide is therefore two orders of magnitude higher than the reported value for glycyrrhizin (K d~1 50 µM). 16 Overall, these results indicate HBP08 as the first selective and potent peptide inhibitor of the CXCL12/HMGB1 heterocomplex, developed so far.
To further characterize the interaction between HBP08 and HMGB1, we performed both experimental and computational alanine scanning of the peptide, comparing the binding affinities of the mutants measured by MST with the change in free energy (∆∆G) estimated by the computational procedure implemented in BioLuminate. 31, 32 (Table 2 ).
The comparison between the experimentally determined K d and the predicted ΔΔG values showed a good agreement. Out of the four mutations with the highest positive binding ∆ ∆ G value predicted (HBP08-Ala3, HBP08-Ala6, HBP08-Ala7 and HBP08-Ala9), three showed a clear decrease in the affinity for HMGB1 measured by MST (HBP08-Ala3, HBP08-Ala7 and HBP08-Ala9). A high positive ∆ ∆ G was estimated also for HBP08-Ala6, in which an arginine residue is mutated in alanine, however this change resulted in a poorly soluble peptide which affinity could be not determined by MST. Concerning the other HBP08
residues, for which smaller binding ∆ ∆ G were predicted, their K d values resulted similar to the value measured for HBP08.
Finally, we also tested the affinity of two peptides formed by the first (pentapept-1) or the last (pentapept-2) five residues of HBP08. Concerning pentapept-1, we did not observe binding in the range of concentration applied to the analysis of the other peptides, while a K d of 160±80 µM was determined for pentapept-2. In summary, both computational and experimental analysis of the binding determinants of HBP08 indicated that the residues at the positions 3, 7 and 9 are the most important for the binding.
To further understand the structural determinants of the individual contributions of these key residues to the binding of the peptide, we analyzed the 3D structure of the HBP08/HMGB1 complex ( Figure 6A , B). From this analysis, HBP08-Arg6 and HBP08-Trp7 form h-bond interactions with Asp67, while HBP08-His9 establishes the same type of interaction with Arg24. Differently, HBP08-His3 is placed in a cavity delimited by Ala17, Val20 and Arg24
and its contribution to the binding seems to be mainly due to VdW interactions.
Finally, we compared the structure of the HBP08/BoxA complex with the one of the CXCL12/BoxA complex, obtained integrating previous NMR investigations 7 and computational modeling 13 ( Figure 6C ). This analysis disclosed that the HBP08 binding site on BoxA is formed by some residues Ala17, Val20, Arg24 and Glu25, important also for the CXCL12 binding. 13 Therefore, the peptide binding might antagonize by competition the formation of the CXCL12/HMGB1 heterocomplex.
HBP08 retro-inverso
L-peptides are susceptible to the action of proteolytic enzymes such as peptidases, hindering their application in vivo. D-peptides are less prone to the action of peptidases and to the acidic hydrolysis that occurs in the stomach, which increases their oral bioavailability and half-live in the blood circulation. Furthermore D-peptides have a lower immunogenicity. 33 Taken together, all these features make D-peptides more suitable for drug development. 34 To exploit the potential of D-peptides, we investigated the binding of a retro-inverso analog of HBP08 (HBP08-RI) made by D-amino acids in reversed order. The results of the binding experiments indicated that HBP08-RI has a good affinity for HMGB1 (K d = 14.0 ± 4.5 µM) and represents, therefore, a good candidate for future drug development studies.
Discussion
Over the last years, several reports have demonstrated the relevance of the CXCL12/HMGB1
heterocomplex both in physiological and in pathological processes. Recently, the CXCL12/HMGB1 heterocomplex has been shown to be crucial in the perpetuation of the chronic inflammation observed in RA, by fueling the recruitment of immune cells. 8 Several therapeutic approaches based on the use of biologic and synthetic therapies are currently in use for the treatment of RA, but a portion of patients does not benefit of the available treatments and only the 20-30% of them reach a low disease activity status. 35, 36 Interestingly, Pitzalis and coworkers have recently pointed out that the composition of the synovial tissue of patients with RA can be related with the response to therapies. 35 We have recently shown that the CXCL12/HMGB1 heterocomplex is present in the synovial fluids of patients affected by RA, and that its function is maintained in patients with active disease. 8 Therefore, small molecules or peptides able to hinder the formation of this heterocomplex could be useful as novel personalized therapeutic strategies.
Multiple attempts have been made to identify small molecules able to bind HMGB1. 19 The majority of inhibitors reported in literature so far show a weak affinity for HMGB1, and are not selectively targeting its synergistic interaction with CXCL12. 16 Recently, diflunisal has been reported as a specific inhibitor of the CXCL12/HMGB1 heterocomplex activity, without affecting the TLR4 signaling, but its Kd for HMGB1 is only in the mM range. 18 Peptides are considered a class of molecules particularly suitable to target protein-protein interaction and they are attracting a renewed interest by medicinal chemists. 37 Therefore, we have applied a computational pipeline to design peptides able to inhibit the formation of the CXCL12/HMGB1 heterocomplex.
Out of the 13 candidates selected with the computational procedure, HBP08 resulted to be able to efficiently inhibit the synergy induced by the heterocomplex on murine cells transfected with the human CXCR4 and on human monocytes. HBP08 and its retro-inverso version bind to HMGB1 with an affinity greater than glycyrrhizin or diflunisal, representing new molecular tools to be exploited for further investigating in vitro and in vivo the role of the CXCL12/HMGB1 heterocomplex in different inflammatory conditions.
Previous studies of Al-Abed and coworkers 38 indicated that the TLR4 activation by HMGB1
can be inhibited by both BoxA and an anti-HMGB1 antibody (2G7) that interacts with HMGB1 binding to the region within the residues 53-63 of BoxA. 39 These results indicated that the same region, far from those we identified for the HBP08 binding, should be responsible of the HMGB1/TLR4 interaction, and in fact we have demonstrated that the developed peptide does not influence the HMGB1 functions related to the TLR4 axis.
The results presented here, demonstrate how the applied computational pipeline allows the fast and efficient design of peptides able to antagonize protein-protein interaction. We propose its application as a novel strategy for the development of powerful inhibitors of protein-protein complex formation.
Methods
Glycyrrhizin docking to HMGB1. A model of the HMGB1-glycyrrhizin complex was built by ligand docking, starting from NMR HMGB1 structure available in the protein data bank with the code 2YRQ. All the docking calculation were carried out using Glide (Schrodinger Inc.)
in the version 2016-4. 40 The grid necessary to perform docking was centered in the COG (center of geometry) of the protein and both the enclosing and the bounding box were set bigger than entire protein, to allow a blind-docking, i.e. docking without previous knowledge of a binding site. Standard precision (SP) mode was used to score the resulting ligand-protein complexes.
The twenty poses with the best Glide score were kept for further investigation. Finally, the structure with the best agreement with NMR chemical shifts perturbation (CSP) data by Mollica et al. 16 was selected as the most likely representative model of the HMGB1glycyrrhizin complex.
Computational design of binding peptides. Peptides were designed following a multistep process. First, the model of the BoxA-glycyrrhizin complex was used to define the target binding site for the peptides. To this end, we selected all amino acids from BoxA for which at least a carbon atom was at a distance smaller than 7.5 Å from a glycyrrhizin carbon atom.
These gave a list of 17 amino acids, namely: LYS_12, MET_13, SER_14, SER_15, TRY_16, ALA_17, VAL_20, GLU_21, ARG_24, GLU_25, LYS_28, SER_35, VAL_36, ASN_37, PHE_38, PHE_41, SER_42.
Since the size of glycyrrhizin is approximatively equal to the length of a linear 9-residue peptide we proceeded with the generation of 40,000 9-residue peptides with a random sequence. All these peptides were then docked on the BoxA domain using the torsional angular molecular dynamics (TMD) module 41, 42 of the software package ALMOST. 43 The docking of the peptides was guided by a set of 17 synthetic NMR-like ambiguous upperdistance restraints 44 between the Cα atoms, ݅ , of the residues of the binding site of BoxA and the Cα atoms, ݆ , of the peptide,
For each peptide, the structure with the smallest distance restraint violations among the 25 generated was then selected and minimized with the CHARMM 19 SASA implicit solvation force field. 45 All peptides where then ranked according to their binding energy,
, and the best 100 among the 40,000 generated were selected for the further analysis.
Peptide re-docking with Glide. The ability of the 100 peptides with the best CHARMM binding energy to form complexes with the BoxA domain of HMGB1 was then additionally assessed with the peptide-docking protocol of Glide, 46 implemented in the Schrodinger suite for molecular modeling (Version 2016-4).
Aiming to leave the algorithm free to explore the entire surface of the protein we performed, also in this case, blind docking using a grid positioned in the center of geometry (COG) and large enough to contain the entire BoxA.
For each peptide, the 15 best poses were saved for further analysis, resulting in a total of Molecular dynamics (MD) and binding free energy calculations. To further asses the stability of the 57 selected complexes and to better estimate their affinity, we performed 0.5 µs MD simulations in explicit water using AMBER16. Snapshots from the corresponding trajectories were extracted to compute the binding energy ∆ G with MM-GBSA, a computational method already applied in similar studies with positive results. 30, 47, 48 All the peptide-BoxA complexes were solvated in a water box with a minimum distance from the protein surface of 10 Å. The total charge of the system was neutralized adding a proper number of Cl -/Na + ions.
All molecular dynamics simulations were carried out using the ff14SB 49 force field for the protein, the TIP3P model 50 for water, and the parameters proposed by Joung et al. 51 Subsequently, the velocities were assigned again, and the systems equilibrated for 20ps at constant pressure (1 Atm). Finally, all complexes were simulated for 500 ns. All the simulations were analyzed and only those in which the peptide -BoxA complex was stable, were retained for MM-GBSA analysis. 500 snapshots selected in the more stable part of the simulation were used in the MM-GBSA calculations. Water molecules and counter-ions were stripped, while the protein and the peptide were parametrized using the same force field as in MD simulations. The polar contribution to solvation energy was computed with the Onufriev, Bashford and Case model setting the dielectric constant to 1 for the solute and 80 for the solvent. 52 Finally, the 13 peptides (Table 1) with the best free energy ∆ G were purchased and tested experimentally in vitro.
Computational Alanine Scanning. The difference in affinity between the mutate peptides and HMGB1 was calculated by the residue scanning functionality of Bioluminate. Starting from the HBP08 pose obtained by docking all residues were mutated, one at the time, to alanine.
The structure of the complex between the mutated HBP08 and HMGB1 was then refined by the side-chain prediction and backbone minimization procedure. Finally, the change in the binding free energy (ΔΔG) has been estimated by the Prime MM-GBSA procedure (OPLS2005 force field 53 and VSGB2.1 solvent model). 31 Proteins and peptides. CXCL12 was chemically synthesized as previously. 54 Histidine tagged HMGB1 was produced at the Institute of Research in Biomedicine Protein Facility (Bellinzona, Switzerland) as previously described, 12 and stored in phosphate-buffered saline (PBS; D8537, Sigma Aldrich, Saint Louis, MO, USA). All the peptides were customsynthesized and HPLC-purified by GenScript (New Jersey, USA). Peptides were reconstituted with DMSO and stored at -20 ºC. HPLC-MS was used to confirm 98% or higher purity for each peptide. Chemotaxis assay. Chemotaxis was performed using Boyden chambers with 5µm pore membranes, as previously described 55 . Murine 300. 19 PreB cells stably transfected with the human CXCR4, or freshly isolated human monocytes were allowed to migrate for 90 min at 37°C in response to a sub-optimal CXCL12 concentration (1 nM), in the presence or absence of HMGB1 (300 nM), as previously described 7 Acquisition was performed with FACSCanto II (BD Biosciences, San Jose, CA), and the concentration was calculated from the MFI according to a standard curve of each cytokine. Table 2 . Equilibrium dissociation constant (K d ) and predicted binding energy (ΔΔG) for the complexes between HMGB1 and the peptide of the first column
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